The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) (IMPULsKF)
Gout, CKD Stage 1-4, SUA Level (>8 mg/dL; 480 µmol/L)
About this trial
This is an interventional treatment trial for Gout focused on measuring eGFR, gout, CKD, uric acid, uric acid lowering therapy, hyperuricemia, allopurinol, febuxostat
Eligibility Criteria
Inclusion Criteria:
- outpatient adults withgout and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)
- outpatient adults with CKD 1-4 stages and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)
Exclusion Criteria:
- CKD 5 stage
- heart failure III-IV NYHA
- stroke
- peripheral arterial disease
- obesity with BMI above 30 kg/m2
- hypertension 3 grade
- insulin-dependent DM
- any kind of cancer
- inpatient intensive unit patients.
Sites / Locations
- Medical Practice Prof D.Ivanov
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Hyperurecemia with gout
Hyperurecemia without gout
90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)